- Home
- OCEA vs FGEN Comparison
OCEA vs FGEN Comparison
Compare OCEA & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEA
- FGEN
- Stock Information
- Founded
- OCEA 2019
- FGEN 1993
- Country
- OCEA United States
- FGEN United States
- Employees
- OCEA N/A
- FGEN N/A
- Industry
- OCEA Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- OCEA Health Care
- FGEN Health Care
- Exchange
- OCEA Nasdaq
- FGEN Nasdaq
- Market Cap
- OCEA 30.4M
- FGEN 34.0M
- IPO Year
- OCEA N/A
- FGEN 2014
- Fundamental
- Price
- OCEA $0.72
- FGEN $0.33
- Analyst Decision
- OCEA
- FGEN
- Analyst Count
- OCEA 0
- FGEN 0
- Target Price
- OCEA N/A
- FGEN N/A
- AVG Volume (30 Days)
- OCEA 48.2K
- FGEN 1.6M
- Earning Date
- OCEA 11-26-2024
- FGEN 11-12-2024
- Dividend Yield
- OCEA N/A
- FGEN N/A
- EPS Growth
- OCEA N/A
- FGEN N/A
- EPS
- OCEA N/A
- FGEN N/A
- Revenue
- OCEA N/A
- FGEN $180,015,000.00
- Revenue This Year
- OCEA N/A
- FGEN $20.42
- Revenue Next Year
- OCEA N/A
- FGEN N/A
- P/E Ratio
- OCEA N/A
- FGEN N/A
- Revenue Growth
- OCEA N/A
- FGEN 16.15
- 52 Week Low
- OCEA $0.52
- FGEN $0.18
- 52 Week High
- OCEA $7.79
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- OCEA 29.58
- FGEN 48.26
- Support Level
- OCEA $0.83
- FGEN $0.18
- Resistance Level
- OCEA $1.00
- FGEN $0.43
- Average True Range (ATR)
- OCEA 0.06
- FGEN 0.05
- MACD
- OCEA -0.02
- FGEN 0.01
- Stochastic Oscillator
- OCEA 24.93
- FGEN 63.14
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.